In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems - PubMed

Review

In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems

Herbert Y Meltzer et al. Prog Brain Res. 2008.

Abstract

Atypical antipsychotic drugs related to clozapine, improve psychosis, cognition and negative symptoms, while producing minimal extrapyramidal side effects, in patients with schizophrenia. This appears to be mediated mainly through the combined effect of relatively more potent blockade of 5-HT(2A) receptors, located on cortical and hippocampal glutamatergic and GABAergic neurons, as well as cell bodies of the mesolimbic and mesocortical dopamine (DA) neurons, and weaker blockade of D(2) receptors in the ventral and dorsal striatum and pyramidal neurons in cortical areas, as well as the cell bodies of DA neurons. This combination of effects is important to their ability to enhance cortical and hippocampal DA efflux, which, while producing less increase of DA efflux in the striatum. Selective inverse agonists of 5-HT(2A) receptors alone, or in combination with subthreshold doses of atypical antipsychotic drugs have shown effects similar to those of atypicals in both animal models and clinical trials in patients with schizophrenia. Atypical antipsychotic drugs and 5-HT(2A) receptor antagonists/inverse agonists have been found to prevent or reverse acute and chronic effects of the N-methyl-D-aspartate non-competitive antagonist, phencyclidine (PCP), including cognitive impairment, in part through enhancing the turnover of DA in cortex. PET, postmortem and genetic studies, as well as clinical studies with 5-HT(2A) hallucinogens, strongly support the importance of 5-HT(2A) receptor blockade in the action of atypical antipsychotic drugs. Their 5-HT(1A) receptor partial agonism, produced directly or indirectly, also contributes to enhancement of efflux of DA in cortical regions. Other serotonergic actions, e.g. 5-HT(2C), 5-HT(6) and possibly 5-HT(7) antagonism, may also contribute to their efficacy or, in the case of 5-HT(2C) antagonism, side effects such as weight gain.

Similar articles

• The role of serotonin receptors in the action of atypical antipsychotic drugs.

  Meltzer HY, Massey BW. Meltzer HY, et al. Curr Opin Pharmacol. 2011 Feb;11(1):59-67. doi: 10.1016/j.coph.2011.02.007. Epub 2011 Mar 21. Curr Opin Pharmacol. 2011. PMID: 21420906 Review.

• Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin-dopamine hypothesis.

  Kuroki T, Nagao N, Nakahara T. Kuroki T, et al. Prog Brain Res. 2008;172:199-212. doi: 10.1016/S0079-6123(08)00910-2. Prog Brain Res. 2008. PMID: 18772034 Review.

• Serotonin receptors: their key role in drugs to treat schizophrenia.

  Meltzer HY, Li Z, Kaneda Y, Ichikawa J. Meltzer HY, et al. Prog Neuropsychopharmacol Biol Psychiatry. 2003 Oct;27(7):1159-72. doi: 10.1016/j.pnpbp.2003.09.010. Prog Neuropsychopharmacol Biol Psychiatry. 2003. PMID: 14642974 Review.

• Role of serotonin and dopamine receptor binding in antipsychotic efficacy.

  Richtand NM, Welge JA, Logue AD, Keck PE Jr, Strakowski SM, McNamara RK. Richtand NM, et al. Prog Brain Res. 2008;172:155-75. doi: 10.1016/S0079-6123(08)00908-4. Prog Brain Res. 2008. PMID: 18772032

• The roles of dopamine and serotonin, and of their receptors, in regulating sleep and waking.

  Monti JM, Jantos H. Monti JM, et al. Prog Brain Res. 2008;172:625-46. doi: 10.1016/S0079-6123(08)00929-1. Prog Brain Res. 2008. PMID: 18772053 Review.

Cited by

• Decoding the signaling of a GPCR heteromeric complex reveals a unifying mechanism of action of antipsychotic drugs.

  Fribourg M, Moreno JL, Holloway T, Provasi D, Baki L, Mahajan R, Park G, Adney SK, Hatcher C, Eltit JM, Ruta JD, Albizu L, Li Z, Umali A, Shim J, Fabiato A, MacKerell AD Jr, Brezina V, Sealfon SC, Filizola M, González-Maeso J, Logothetis DE. Fribourg M, et al. Cell. 2011 Nov 23;147(5):1011-23. doi: 10.1016/j.cell.2011.09.055. Cell. 2011. PMID: 22118459 Free PMC article.

• The novel antipsychotic drug lurasidone enhances N-methyl-D-aspartate receptor-mediated synaptic responses.

  Yuen EY, Li X, Wei J, Horiguchi M, Meltzer HY, Yan Z. Yuen EY, et al. Mol Pharmacol. 2012 Feb;81(2):113-9. doi: 10.1124/mol.111.076141. Epub 2011 Nov 9. Mol Pharmacol. 2012. PMID: 22072817 Free PMC article.

• Second generation antipsychotic-induced obsessive-compulsive symptoms in schizophrenia: a review of the experimental literature.

  Fonseka TM, Richter MA, Müller DJ. Fonseka TM, et al. Curr Psychiatry Rep. 2014 Nov;16(11):510. doi: 10.1007/s11920-014-0510-8. Curr Psychiatry Rep. 2014. PMID: 25256097 Review.

• Ring substituents on substituted benzamide ligands indirectly mediate interactions with position 7.39 of transmembrane helix 7 of the D4 dopamine receptor.

  Ericksen SS, Cummings DF, Teer ME, Amdani S, Schetz JA. Ericksen SS, et al. J Pharmacol Exp Ther. 2012 Aug;342(2):472-85. doi: 10.1124/jpet.112.193979. Epub 2012 May 15. J Pharmacol Exp Ther. 2012. PMID: 22588261 Free PMC article.

• Histone deacetylase inhibitors mitigate antipsychotic risperidone-induced motor side effects in aged mice and in a mouse model of Alzheimer's disease.

  Rodriguez G, Fisher DW, McClarty B, Montalvo-Ortiz J, Cui Q, Chan CS, Dong H. Rodriguez G, et al. Front Psychiatry. 2023 Jan 6;13:1020831. doi: 10.3389/fpsyt.2022.1020831. eCollection 2022. Front Psychiatry. 2023. PMID: 36684015 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science

• Other Literature Sources

  • The Lens - Patent Citations Database